Royalty Pharma (RPRX) Payables (2019 - 2026)

Royalty Pharma has disclosed Payables across 8 years of filings, most recently posting $35.6 million for Q2 2026.

• In Q2 2026, Payables rose 75.99% year-over-year to $35.6 million; the TTM figure through Jun 2026 stood at $35.6 million (up 75.99% YoY), while the FY2025 annual figure was $19.4 million, up 45.13% from the prior year.
• Payables came in at $35.6 million for Q2 2026 at Royalty Pharma, up from $25.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $128.2 million in Q2 2022 to a low of $5.8 million in Q2 2023.
• Average Payables over 5 years is $48.1 million, with a median of $24.4 million recorded in 2024.
• Year-over-year, Payables tumbled 95.47% in 2023 and jumped 303.1% in 2024.
• Over 5 years, Payables stood at $102.7 million in 2022, then sank by 85.23% to $15.2 million in 2023, then slipped by 11.84% to $13.4 million in 2024, then soared by 45.13% to $19.4 million in 2025, then jumped by 83.29% to $35.6 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $35.6 million in Q2 2026, $25.5 million in Q1 2026, and $19.4 million in Q4 2025.